131 related articles for article (PubMed ID: 25451186)
1. Comparison of PEGylated FGF-21 with insulin glargine for long-lasting hypoglycaemic effect in db/db mice.
Ye X; Qi J; Wu Y; Yu D; Xu P; Li S; Zhu S; Wu Q; Ren G; Li D
Diabetes Metab; 2015 Feb; 41(1):82-90. PubMed ID: 25451186
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting anti-diabetic efficacy of PEGylated FGF-21 and liraglutide in treatment of type 2 diabetic mice.
Ye X; Qi J; Ren G; Xu P; Wu Y; Zhu S; Yu D; Li S; Wu Q; Muhi RL; Li D
Endocrine; 2015 Aug; 49(3):683-92. PubMed ID: 25557015
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a combination of high and low dosage of PEGylated FGF-21 in treatment of diabetes in db/db mice.
Xu P; Zhang Y; Song L; Khoso MH; Li J; Jiang X; He J; Li J; Ma X; Ren G; Li D
Biomed Pharmacother; 2016 Dec; 84():97-105. PubMed ID: 27643551
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
5. Long-acting hypoglycemic effects of PEGylated FGF21 and insulin glargine in mice with type 1 diabetes.
Xu P; Ye X; Zhang Y; Yuan Q; Liu M; Wu Q; Ren G; Li D
J Diabetes Complications; 2015; 29(1):5-12. PubMed ID: 25456819
[TBL] [Abstract][Full Text] [Related]
6. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation.
Ye X; Qi J; Sun G; Ren G; Zhu S; Wu Y; Yu D; Zhao J; Liu M; Li D
Curr Pharm Biotechnol; 2013; 14(15):1287-98. PubMed ID: 25106652
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting hypoglycemic effect of modified FGF-21 analog with polyethylene glycol in type 1 diabetic mice and its systematic toxicity.
Ye X; Qi J; Wu Q; Yu D; Li S; Wu Y; Li D
Eur J Pharmacol; 2016 Jun; 781():198-208. PubMed ID: 27089817
[TBL] [Abstract][Full Text] [Related]
9. Pilot-scale production and characterization of PEGylated human FGF-21 analog.
Ye X; Qi J; Yu D; Li S; Wu Q; Wu Y; Ren G; Han J; Li D
J Biotechnol; 2016 Jun; 228():8-17. PubMed ID: 27109774
[TBL] [Abstract][Full Text] [Related]
10. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol.
Huang Z; Wang H; Lu M; Sun C; Wu X; Tan Y; Ye C; Zhu G; Wang X; Cai L; Li X
PLoS One; 2011; 6(6):e20669. PubMed ID: 21673953
[TBL] [Abstract][Full Text] [Related]
11. PEGylated insulin Lispro, (LY2605541)--a new basal insulin analogue.
Caparrotta TM; Evans M
Diabetes Obes Metab; 2014 May; 16(5):388-95. PubMed ID: 23941279
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
13. Effects of the novel oral antidiabetic agent HQL-975 on glucose and lipid metabolism in diabetic db/db mice.
Ishikawa Y; Watanabe K; Takeno H; Tani T
Arzneimittelforschung; 1998 Mar; 48(3):245-50. PubMed ID: 9553681
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
Yamanaka M; Itakura Y; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Diabetes Obes Metab; 2007 Nov; 9(6):879-88. PubMed ID: 17924870
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic and hypolipidemic action of Du-zhong (Eucommia ulmoides Oliver) leaves water extract in C57BL/KsJ-db/db mice.
Park SA; Choi MS; Kim MJ; Jung UJ; Kim HJ; Park KK; Noh HJ; Park HM; Park YB; Lee JS; Lee MK
J Ethnopharmacol; 2006 Oct; 107(3):412-7. PubMed ID: 16684593
[TBL] [Abstract][Full Text] [Related]
16. The anti-diabetic effects of ethanol extract from two variants of Artemisia princeps Pampanini in C57BL/KsJ-db/db mice.
Jung UJ; Baek NI; Chung HG; Bang MH; Yoo JS; Jeong TS; Lee KT; Kang YJ; Lee MK; Kim HJ; Yeo JY; Choi MS
Food Chem Toxicol; 2007 Oct; 45(10):2022-9. PubMed ID: 17574717
[TBL] [Abstract][Full Text] [Related]
17. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes?
Maiorino MI; Petrizzo M; Capuano A; Giugliano D; Esposito K
Expert Opin Biol Ther; 2014 Jun; 14(6):799-808. PubMed ID: 24673155
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
[TBL] [Abstract][Full Text] [Related]
19. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects.
Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C
Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844
[TBL] [Abstract][Full Text] [Related]
20. A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti-hyperglycaemic medication: results of the PARADIGM study.
Bowering K; Reed VA; Felicio JS; Landry J; Ji L; Oliveira J
Diabet Med; 2012 Sep; 29(9):e263-72. PubMed ID: 22672081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
